Syros Pharmaceuticals
Syros Pharmaceuticals
SYRS
NASDAQ
0.09
USD
-35.71%
About
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML).
Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 207.0K |
| Three Month Average Volume | 5.0M |
| High Low | |
| Fifty-Two Week High | 8.17 USD |
| Fifty-Two Week Low | 1.48 USD |
| Fifty-Two Week High Date | 02 Jan 2024 |
| Fifty-Two Week Low Date | 16 Aug 2024 |
| Price and Volume | |
| Current Price | 1.64 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -71.62% |
| Thirteen Week Relative Price Change | -69.95% |
| Twenty-Six Week Relative Price Change | -80.75% |
| Fifty-Two Week Relative Price Change | -66.44% |
| Year-to-Date Relative Price Change | -82.22% |
| Price Change | |
| One Day Price Change | -1.20% |
| Thirteen Week Price Change | -67.84% |
| Twenty-Six Week Price Change | -78.84% |
| Five Day Price Change | -1.20% |
| Fifty-Two Week Price Change | -57.95% |
| Year-to-Date Price Change | -78.95% |
| Month-to-Date Price Change | -72.67% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.62997 USD |
| Book Value Per Share (Most Recent Quarter) | -0.23693 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.62997 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.23693 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.41681 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.35078 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.12219 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -5.81004 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -4.30174 USD |
| Normalized (Last Fiscal Year) | -5.72217 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -5.81004 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -4.30174 USD |
| Including Extraordinary Items (Last Fiscal Year) | -5.81004 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -4.30174 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.27535 USD |
| Cash Per Share (Most Recent Quarter) | 2.94535 USD |
| Cash Flow Per Share (Last Fiscal Year) | -5.72884 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.82738 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.27624 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -717 |
| Cash Flow Revenue (Trailing Twelve Months) | -2,681 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -3,171.70% |
| Pretax Margin (Last Fiscal Year) | -1,656.34% |
| Pretax Margin (5 Year) | -772.82% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,298.19% |
| Operating Margin (Trailing Twelve Months) | -2,895.69% |
| Operating Margin (5 Year) | -801.97% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,656.34% |
| Net Profit Margin (Trailing Twelve Months) | -3,171.70% |
| Net Profit Margin (5 Year) | -772.82% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -51.42% |
| Tangible Book Value (5 Year) | -26.67% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | 37.12% |
| Revenue Change (Trailing Twelve Months) | -53.52% |
| Revenue Per Share Growth | -10.99% |
| Revenue Growth (5 Year) | -13.01% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -27.78% |
| Total Debt (5 Year) | 321.46% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 54.27% |
| EPS Change (Trailing Twelve Months) | -1,577.09% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -38,030,000 |
| Net Debt (Last Fiscal Year) | -98,303,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 11 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 3 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 3 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 207 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -109,979,000 |
| Free Cash Flow (Trailing Twelve Months) | -111,223,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 247 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -79.76% |
| Return on Assets (Trailing Twelve Months) | -91.46% |
| Return on Assets (5 Year) | -54.44% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -227.95% |
| Return on Equity (Trailing Twelve Months) | -393.39% |
| Return on Equity (5 Year) | -117.42% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -95.35% |
| Return on Investment (Trailing Twelve Months) | -112.06% |
| Return on Investment (5 Year) | -64.32% |